A Phase 1, randomized, drug-interaction, and food effect study to assess the safety, tolerability, and pharmacokinetics of INCB086550 when administered orally to healthy adult participants.
Latest Information Update: 03 Feb 2021
At a glance
- Drugs INCB 086550 (Primary) ; Esomeprazole; Famotidine; Itraconazole; Rifampicin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Incyte Corporation
- 03 Feb 2021 New trial record